Kieron Dunleavy, MD; Catherine Bollard, MD, MBChB #HemeWorkshop2020

5:42

Catherine Bollard talks to Kieron Dunleavy about the expanding field of cell therapy, from BCMA targeted CAR T cells nearing approval to early-phase studies with multi-antigen specific T cells.

Mitchell Smith, MD, PhD; GW Cancer Center; 5Live #ASH20

5:20

Key insights from the 2020 Annual Hematology meeting in Lymphoma

Loretta Nastoupil, MD; University of Texas MD Anderson Cancer Center; 5Live #ASH20

7:43

Key insights from the 2020 Annual Hematology meeting in Lymphoma

Julie Vose, MD, MBA, FASCO; University of Nebraska Medical Center; 5Live #ASH20

1:54

Key insights from the 2020 Annual Hematology meeting in Lymphoma

John P. Leonard, MD; #VCCB-cellUpdatesFromASCO-EHA2020

47:13

Paolo Strati, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20

5:45

Key insights on Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).

Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20

4:51

Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

Michael Wang, MD; University of Texas MD Anderson Cancer Center 5Live #ASCO20

8:25

Key Insights on Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.

Martin Hutchings, MD, PhD Rigshospitalet, Copenhagen Denmark 5Live #ASCO20

6:23

Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.

Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020

5:08

Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)

Constantine Si Lun Tam, MBBS, MD Peter MacCallum Cancer Centre University of Melbourne 5Live #ASCO20

1:43

Key Insights on Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib